Testing KIVU-107 in advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug, KIVU-107, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug is safe and helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is a solid tumor that has spread (metastatic) or is locally advanced and has not responded to or is not eligible for standard treatments.
- You are in reasonably good health otherwise, with adequate bone marrow, kidney, and liver function.
- Your cancer can be measured on imaging scans (like CT or MRI).
- You are still able to do most daily activities (ECOG score 0 or 1).
- You have not had prior treatment with a specific type of drug called an antibody-drug conjugate (ADC) that contains a topoisomerase 1 inhibitor (like irinotecan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This study tests a new cancer drug called KIVU-305 in people with advanced or metastatic solid tumors (cancer that has spread) that haven't responded to standard treatments. The drug is designed to target cancer cells while minimizing harm to healthy cells.
This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug called VIB305 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if VIB305 is safe and how it affects the tumors.
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.